The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-12 and is reviewed periodically as new material appears.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
In the molecule lawrencium dihydride (LrH2), which is predicted to be bent, the 6d orbital of lawrencium is not expected to play a role in the bonding, unlike that of lanthanum dihydride (LaH2). LaH2 has La–H bond distances of 2.158 Å, while LrH2 should have shorter Lr–H bond distances of 2.042 Å due to the relativistic contraction and stabilization of the 7s and 7p orbitals involved in the bonding, in contrast to the core-like 5f subshell and the mostly uninvolved 6d subshell. In general, molecular LrH2 and LrH are expected to resemble the corresponding thallium species (thallium having a 6s26p1 valence configuration in the gas phase, like lawrencium's 7s27p1) more than the corresponding lanthanide species. The electron configurations of Lr+ and Lr2+ are expected to be 7s2 and 7s1 respectively. However, in species where all three valence electrons of lawrencium are ionized to give at least formally the Lr3+ cation, lawrencium is expected to behave like a typical actinide and the heavier congener of lutetium, especially because the first three ionization potentials of lawrencium are predicted to be similar to those of lutetium. Hence, unlike thallium but like lutetium, lawrencium would prefer to form LrH3 than LrH, and LrCO is expected to be similar to the also unknown LuCO, both metals having valence configuration σ2π1 in their monocarbonyls. The pπ–dπ bond is expected to be seen in LrCl3 just as it is for LuCl3 and more generally all the LnCl3.
==== Snuff ==== Snuff is a type of smokeless tobacco product made from finely ground or pulverized tobacco leaves. It is snorted or "sniffed" (alternatively sometimes written as "snuffed") into the nasal cavity, delivering nicotine and a flavored scent to the user (especially if flavoring has been blended with the tobacco). Traditionally, it is sniffed or inhaled lightly after a pinch of snuff is either placed onto the back surface of the hand, held pinched between thumb and index finger, or held by a specially made "snuffing" device.
==== Harley ==== Ricky Legere fights a bully named Harley, to defend a French kid. The bully only taps out one time in the first round, and stands through the second one, leaving the bully with $9000.
== History == Biocatalysis underpins some of the oldest chemical transformations known to humans, for brewing predates recorded history. The oldest records of brewing are about 6000 years old and refer to the Sumerians. The employment of enzymes and whole cells have been important for many industries for centuries. The most obvious uses have been in the food and drink businesses where the production of wine, beer, cheese etc. is dependent on the effects of the microorganisms. More than one hundred years ago, biocatalysis was employed to do chemical transformations on non-natural man-made organic compounds, with the last 30 years seeing a substantial increase in the application of biocatalysis to produce fine chemicals, especially for the pharmaceutical industry. Since biocatalysis deals with enzymes and microorganisms, it is historically classified separately from "homogeneous catalysis" and "heterogeneous catalysis". However, mechanistically speaking, biocatalysis is simply a special case of heterogeneous catalysis.
Springer's lab screened for such activity in cell line supernatants, purified and sequenced the protein, and found that stromal derived factor (SDF-1), previously defined as a growth factor for B cells, was a potent chemoattractant for both B and T cells. SDF-1 activated an orphan GPCR, later named CXCR4, which was also the co-receptor for T-cell-tropic HIV; SDF-1 further blocked infection of T cells by HIV. SDF-1 (CXCL12) is also a chemoattractant for CD34+ hematopoietic stem cells and regulates their movement from bone marrow to the bloodstream. Based on these discoveries, plerixafor (Mozobil) was developed as an antagonist of CXCR4 and is approved, in combination with filgrastim, for use in mobilizing hematopoietic stem cells in patients with multiple myeloma or non-Hodgkin lymphoma. In later retrospective discussion, Springer framed the three steps in leukocyte emigration into inflammatory sites as an “area code” model, emphasizing that each step requires a cognate receptor–ligand interaction and therefore provides multiple intervention points (selectins and ligands; GPCRs and ligands; integrins including LFA-1, α4β1, α4β7 and endothelial ligands). He argued that the size of the target space exceeded what could be pursued in an academic laboratory and helped motivate company formation.
Sources: en.wikipedia.org
Inspired by Michael Abrash, who left Microsoft to work on the game Quake at id, Newell and another employee, Mike Harrington, left Microsoft to found the video game company Valve on August 24, 1996. Newell opted to found Valve instead of retiring as he felt working with "other really smart, motivated, socially orientated people to create product that would affect millions of other people" would be more fun. Newell and Harrington funded development of the first Valve game, the first-person shooter Half-Life (1998), which was a critical and commercial success. Harrington sold his stake in Valve to Newell in 2000. Newell gave Valve no deadline and a "virtually unlimited" budget to develop Half-Life 2 (2004), promising to fund it himself if necessary. He and Valve came close to bankruptcy during a legal battle with Vivendi Games, which ended when an intern discovered an email revealing that Vivendi was destroying evidence.
The limitations of 3D bioprinting are associated with physiologically irrelevant morphology and unsuccessful histological evaluation methods. 3D bioprinting contributes to significant advances in the medical field of tissue engineering by allowing for research to be done on innovative materials called biomaterials. Some of the most notable bioengineered substances are usually stronger than the average bodily materials, including soft tissue and bone. These constituents can act as future substitutes, even improvements, for the original body materials. In addition, the Defense Threat Reduction Agency aims to print mini organs such as hearts, livers, and lungs as the potential to test new drugs more accurately and perhaps eliminate the need for testing in animals. For bioprinted food like meat see #Food and drink.
==== VGluT3 ==== VGluT3 (Vesicular Glutamate Transporter 3) that is encoded by the SLC17A8 gene is a member of the vesicular glutamate transporter family that transports glutamate into the cells. It is involved in neurological and pain diseases. Neurons are able to express VGluT3 when they use a neurotransmitter different to Glutamate, for example in the specific case of central 5-HT neurons. The role of this unconventional transporter (VGluT3) still remains unknown but, at the moment, has been demonstrated that, in auditory system, the VGluT3 is involved in fast excitatory glutamatergic transmission very similar to the other two vesicular glutamate transporters, VGluT1 and VGluT2. There are behavioral and physiological consequences of VGluT3 ablation because it modulates a wide range of neuronal and physiological processes like anxiety, mood regulation, impulsivity, aggressive behavior, pain perception, sleep–wake cycle, appetite, body temperature and sexual behavior. Certainly, no significant change was found in aggression and depression-like behaviors, but in contrast, the loss of VGluT3 resulted in a specific anxiety-related phenotype. The sensory nerve fibers have different ways to detect the pain hypersensivity throughout their sensory modalities and conduction velocities, but at the moment is still unknown which types of sensory is related to the different forms of inflammatory and neuropathic pain hypersensivity.
== Honors and awards == 1981–1982: Fogarty International Scholar 1981: Honorary Member of the American Society of Biological Chemistry 1984: Rothschild Prize in Chemistry 1987: Wolf Prize in Medicine, jointly with Pedro Cuatrecasas, "for the invention and development of affinity chromatography and its applications to biomedical sciences." 1987: Pierce Prize for Biorecognition Technology 1988: Elected Member of the Israel Academy of Sciences and Humanities 1989: Doctor of Science, honoris causa, University of Waterloo, Canada 1989: Barnett Lecturer, Northeastern University, Boston 1990: Israel Prize, in life sciences 1990: Sarstedt Prize (Numbrecht, Germany) 1993: Foreign Associate Member, Institute of Medicine, National Academy of Science, USA 1995: Doctor of Science, honoris causa, Bar Ilan University, Israel 1996: International Distinguished Clinical Chemist Award, International Federation of Clinical Chemistry (IFCC) 2000: Doctor of Science, honoris causa, University Jyvaskyla, Finland 2000: Honorary Doctorate, Ben-Gurion University of the Negev 2002: Honorary Citizen, City of Rehovot, Israel 2004: Wilhelm Exner Medal. 2004: Christian B. Anfinsen Award of The Protein Society 2004: Wilhelm-Exner Medal, OGV, President of Austria 2005: Emet Prize, presented by the Prime Minister of Israel
=== Regulation of respiration === Carbon dioxide is one of the mediators of local autoregulation of blood supply. If its concentration is high, the capillaries expand to allow a greater blood flow to that tissue. Bicarbonate ions are crucial for regulating blood pH. A person's breathing rate influences the level of CO2 in their blood. Breathing that is too slow or shallow causes respiratory acidosis, while breathing that is too rapid leads to hyperventilation, which can cause respiratory alkalosis. Although the body requires oxygen for metabolism, low oxygen levels normally do not stimulate breathing. Rather, breathing is stimulated by higher carbon dioxide levels. As a result, breathing low-pressure air or a gas mixture with no oxygen at all (such as pure nitrogen) can lead to loss of consciousness without ever experiencing air hunger. This is especially perilous for high-altitude fighter pilots. It is also why flight attendants instruct passengers, in case of loss of cabin pressure, to apply the oxygen mask to themselves first before helping others; otherwise, one risks losing consciousness. The respiratory centers try to maintain an arterial CO2 pressure of 40 mmHg. With intentional hyperventilation, the CO2 content of arterial blood may be lowered to 10–20 mmHg (the oxygen content of the blood is little affected), and the respiratory drive is diminished. This is why one can hold one's breath longer after hyperventilating than without hyperventilating.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.